The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1Safety in GCA ...

If your child is evaluated for an IEP and found eligible, their eligibility will be in one of IDEA eligibility categories. One of the categories is: Multiple Impairments or Multiple Disabilities IEP ...

June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data ...

Nearly 1 in 5 packaged foods and drinks from major U.S. brands contain synthetic dyes, with products aimed at children—like ...

Antimicrobial resistance (AMR) and food biosecurity are pressing global concerns, intertwined within the broader context of ...

The chief data reporter for the Financial Times discusses how he considers the use of text, color, and annotation to aid ...

A new study reveals that the same clinical signs of depression may stem from different brain profiles, highlighting both ...

Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...

Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market insights reveal exciting opportunities. See more.

-- Data being presented at the 32nd Annual FSHD Society International Research Congress (IRC); Investor and analyst webcast event today, Monday, June 9 at 8:00 a.m. ET-- SAN DIEGO, June 9, 2025 ...

Scale AI, which also offers data labeling and evaluation services, is reportedly in talks to finalize a share sale at a $25 billion valuation, up from its $13.8 billion valuation a year ago.

The data presented at AAN covers the period from September 2018 to January 31, 2024, and included 240 patients administered ZYN002 at doses of 250, 500, or 750 mg per day based on their weight.